AAUM (Average Assets Under Management) of ₹18.92 Cr for Apr-Jun 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 76.4% | 75.8% | ▼ -0.7% |
| Healthcare Services | 23.3% | 23.7% | ▲ +0.4% |
| Healthcare Equipment & Supplies | 0.5% | 0.5% | ● +0.1% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 75.8% | 76.1% | ▲ +0.4% |
| Healthcare Services | 23.7% | 23.3% | ▼ -0.5% |
| Healthcare Equipment & Supplies | 0.5% | 0.5% | ● 0.0% |
Comparing Jun 2026 → Jul 2026
| # | Stock | Sector | Weight (Jul 2026) |
|---|---|---|---|
| 1 | Jupiter Life Line Hospitals Limited ₹9.07 L |
Healthcare Services | 0.38% |
| # | Stock | Sector | Last Weight (Jun 2026) |
|---|---|---|---|
| 1 | JB Chemicals & Pharmaceuticals Limited ₹25.80 L |
Pharmaceuticals & Biotechnology | 1.21% |
| 2 | Jupiter Life Line Hospitals Ltd ₹7.29 L |
Healthcare Services | 0.34% |
| # | Stock | Sector | Jun 2026 | Jul 2026 | Change |
|---|---|---|---|---|---|
| 1 | Torrent Pharmaceuticals Limited ₹1.07 Cr |
Pharmaceuticals & Biotechnology | 3.01% | 4.53% | +1.52% |
| 2 | Divi's Laboratories Limited ₹1.51 Cr |
Pharmaceuticals & Biotechnology | 5.37% | 6.38% | +1.01% |
| 3 | Laurus Labs Limited ₹1.02 Cr |
Pharmaceuticals & Biotechnology | 3.73% | 4.33% | +0.60% |
| 4 | Sun Pharmaceutical Industries Limited ₹3.16 Cr |
Pharmaceuticals & Biotechnology | 12.90% | 13.35% | +0.45% |
| 5 | Dr. Lal Path Labs Limited ₹21.63 L |
Healthcare Services | 0.81% | 0.91% | +0.10% |
| 6 | Piramal Pharma Limited ₹18.01 L |
Pharmaceuticals & Biotechnology | 0.67% | 0.76% | +0.09% |
| 7 | Abbott India Limited ₹20.84 L |
Pharmaceuticals & Biotechnology | 0.83% | 0.88% | +0.05% |
| 8 | Sai Life Sciences Limited ₹26.26 L |
Pharmaceuticals & Biotechnology | 1.07% | 1.11% | +0.04% |
| 9 | GlaxoSmithKline Pharmaceuticals Limited ₹15.87 L |
Pharmaceuticals & Biotechnology | 0.64% | 0.67% | +0.03% |
| 10 | Concord Biotech Limited ₹6.99 L |
Pharmaceuticals & Biotechnology | 0.27% | 0.30% | +0.03% |
| # | Stock | Sector | Jun 2026 | Jul 2026 | Change |
|---|---|---|---|---|---|
| 1 | Dr. Reddy's Laboratories Limited ₹1.03 Cr |
Pharmaceuticals & Biotechnology | 5.30% | 4.35% | -0.95% |
| 2 | Max Healthcare Institute Limited ₹1.19 Cr |
Healthcare Services | 5.36% | 5.05% | -0.31% |
| 3 | Acutaas Chemicals Ltd ₹23.50 L |
Pharmaceuticals & Biotechnology | 1.17% | 0.99% | -0.18% |
| 4 | Fortis Healthcare Limited ₹72.36 L |
Healthcare Services | 3.20% | 3.06% | -0.14% |
| 5 | Cipla Limited ₹1.22 Cr |
Pharmaceuticals & Biotechnology | 5.31% | 5.18% | -0.13% |
| 6 | Lupin Limited ₹86.01 L |
Pharmaceuticals & Biotechnology | 3.76% | 3.64% | -0.12% |
| 7 | Mankind Pharma Limited ₹40.48 L |
Pharmaceuticals & Biotechnology | 1.82% | 1.71% | -0.11% |
| 8 | Aurobindo Pharma Limited ₹64.74 L |
Pharmaceuticals & Biotechnology | 2.82% | 2.74% | -0.08% |
| 9 | Syngene International Limited ₹10.74 L |
Healthcare Services | 0.53% | 0.45% | -0.08% |
| 10 | Krishna Institute Of Medical Sciences Limited ₹29.34 L |
Healthcare Services | 1.30% | 1.24% | -0.06% |
125 stocks — Jul 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹3.16 Cr |
Pharmaceuticals & Biotechnology |
13.35%
|
|
| 2 |
₹1.51 Cr |
Pharmaceuticals & Biotechnology |
6.38%
|
|
| 3 |
₹1.34 Cr |
Healthcare Services |
5.68%
|
|
| 4 |
₹1.22 Cr |
Pharmaceuticals & Biotechnology |
5.18%
|
|
| 5 |
₹1.19 Cr |
Healthcare Services |
5.05%
|
|
| 6 |
₹1.07 Cr |
Pharmaceuticals & Biotechnology |
4.53%
|
|
| 7 |
₹1.03 Cr |
Pharmaceuticals & Biotechnology |
4.35%
|
|
| 8 |
₹1.02 Cr |
Pharmaceuticals & Biotechnology |
4.33%
|
|
| 9 |
₹86.01 L |
Pharmaceuticals & Biotechnology |
3.64%
|
|
| 10 |
₹72.36 L |
Healthcare Services |
3.06%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.